Prime Medicine Stock Forecast
NASDAQ: PRMEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
PRME analyst consensus
Consensus (14 analysts)
strong_buy
Avg. price target
$7.11+78.20%
- Strong buy 1
- Buy 10
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 14 Wall Street analysts covering Prime Medicine (2026-10-08), 11 rate the stock a buy or strong buy, 3 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $7.11, with a high estimate of $11.00 and a low estimate of $4.25. The average target implies upside of 78.2% from the current price of $3.99.
The spread between the highest and lowest targets is 158.8%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for PRME.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 7% |
| Buy | 10 | 71% |
| Hold | 3 | 21% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $4.25 | +6.52% |
| Average target | $7.11 | +78.20% |
| High target | $11.00 | +175.69% |